Literature DB >> 17768685

Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.

Jian Gong1, Yunge Zhao, Rana Abdel-Fattah, Samson Amos, Aizhen Xiao, M Beatriz S Lopes, Isa M Hussaini, Edward R Laws.   

Abstract

OBJECT: We analyzed MMP-9 expression using mRNA and protein level determinations and explored the possibility that matrix metalloproteinase-9 (MMP-9) is a potential biological marker of pituitary adenoma invasiveness and whether MMP-9 could be used to discriminate the extent of invasiveness among different hormonal subtypes, tumor sizes, growth characteristics, and primary versus recurrent tumors.
MATERIALS AND METHODS: 73 pituitary tumor specimens were snap frozen in liquid nitrogen immediately after surgical resection. RNA and protein were extracted. MMP-9 mRNA transcripts were analyzed by quantitative RT-PCR. MMP-9 protein activity was analyzed by gelatin zymography and validated by western blot analysis. Immunohistochemistry was performed to identify the presence and localization of MMP-9 in pituitary adenomas. Statistical differences between results were determined using Student's t-test or one way ANOVA.
RESULTS: Comparing different hormonal subtypes of noninvasive and invasive pituitary tumors, MMP-9 mRNA expression was significantly increased in the majority of invasive adenomas. Considering the protein levels, our data also showed a significant increase in MMP-9 activity in the majority of invasive adenomas and these differences were confirmed by western blot analysis and immunohistochemistry. In addition, consistent differences in MMP-9 expression levels were found according to tumor subtype, tumor size, tumor extension and primary versus redo-surgery.
CONCLUSIONS: MMP-9 expression can consistently distinguish invasive pituitary tumors from noninvasive pituitary tumors and would reflect the extent of invasiveness in pituitary tumors according to tumor subtype, size, tumor extension, primary and redo surgery, even at early stages of invasiveness. MMP-9 may be considered a potential biomarker to determine and predict the invasive nature of pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17768685     DOI: 10.1007/s11102-007-0066-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  43 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  Matrix metalloproteinases and their inhibitors in human pituitary tumors.

Authors:  E Beaulieu; Z Kachra; N Mousseau; L Delbecchi; J Hardy; R Béliveau
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

3.  Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis.

Authors:  H Kawamoto; K Kawamoto; T Mizoue; T Uozumi; K Arita; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive?

Authors:  S Yokoyama; H Hirano; K Moroki; M Goto; S Imamura; J I Kuratsu
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

5.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

6.  Role of matrix metalloproteinase 9 in pituitary tumor behavior.

Authors:  H E Turner; Z Nagy; M M Esiri; A L Harris; J A Wass
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

7.  Invasiveness of pituitary adenomas.

Authors:  D Sautner; W Saeger
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

8.  Transsphenoidal surgery of parasellar pituitary adenomas.

Authors:  R Fahlbusch; M Buchfelder
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

9.  Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.

Authors:  Ulrich J Knappe; Christian Hagel; Björn W Lisboa; Waldemar Wilczak; Dieter K Lüdecke; Wolfgang Saeger
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088

10.  Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion.

Authors:  H Watanabe; I Nakanishi; K Yamashita; T Hayakawa; Y Okada
Journal:  J Cell Sci       Date:  1993-04       Impact factor: 5.285

View more
  15 in total

1.  The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.

Authors:  Lubin Qiu; Dongsheng He; Xiang Fan; Zhi Li; Chuangxin Liao; Yonghong Zhu; Haijun Wang
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

2.  Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma.

Authors:  Zhiqiang Xia; Wenqing Liu; Shengdong Li; Ge Jia; Yuqi Zhang; Chunde Li; Zhenyu Ma; Jihui Tian; Jian Gong
Journal:  Neurochem Res       Date:  2011-08-04       Impact factor: 3.996

3.  Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.

Authors:  M Victoria Recouvreux; Lara Lapyckyj; M Andrea Camilletti; M Clara Guida; Ana Ornstein; Daniel B Rifkin; Damasia Becu-Villalobos; Graciela Díaz-Torga
Journal:  Endocrinology       Date:  2013-09-05       Impact factor: 4.736

Review 4.  Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.

Authors:  W Saeger; S Petersenn; C Schöfl; U J Knappe; M Theodoropoulou; R Buslei; J Honegger
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 5.  Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.

Authors:  Busra Aydin; Aysegul Caliskan; Kazim Yalcin Arga
Journal:  EPMA J       Date:  2021-06-26       Impact factor: 8.836

6.  Dural Invasion as a Marker of Aggressive Pituitary Adenomas.

Authors:  Odelia Cooper; Vivien Bonert; Adam N Mamelak; Serguei Bannykh; Shlomo Melmed
Journal:  Neurosurgery       Date:  2022-03-11       Impact factor: 5.315

7.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

8.  Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).

Authors:  Daizo Yoshida; Ryutaro Nomura; Akira Teramoto
Journal:  J Neurooncol       Date:  2008-05-21       Impact factor: 4.130

9.  Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.

Authors:  Jie Feng; Lichuan Hong; Yonggang Wu; Chuzhong Li; Hong Wan; Guilin Li; Yilin Sun; Shenyuan Yu; Prashant Chittiboina; Blake Montgomery; Zhengping Zhuang; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2014-06-11       Impact factor: 4.130

Review 10.  Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials.

Authors:  Hong-Yan Liu; Wei-Jun Gu; Cheng-Zhi Wang; Xiao-Jian Ji; Yi-Ming Mu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.